Investigations of the effectiveness of a novel multiple kinase inhibitor, BPR1K-X, in targeting human pancreatic cancer cells
碩士 === 國立成功大學 === 藥理學研究所 === 102 === Pancreatic cancer is widely known as the most aggressive solid malignancies with poor prognosis. The overall 5-year survival is 6%, and the standard treatment with gemcitabine only yields a median survival of 5.6 months in advanced disease. Therefore, developing...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2014
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/11179646527647483648 |